325 related articles for article (PubMed ID: 22419750)
1. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.
Ridker PM; MacFadyen JG; Wolfert RL; Koenig W
Clin Chem; 2012 May; 58(5):877-86. PubMed ID: 22419750
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy.
Chu AY; Guilianini F; Grallert H; Dupuis J; Ballantyne CM; Barratt BJ; Nyberg F; Chasman DI; Ridker PM
Circ Cardiovasc Genet; 2012 Dec; 5(6):676-85. PubMed ID: 23118302
[TBL] [Abstract][Full Text] [Related]
3. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
[TBL] [Abstract][Full Text] [Related]
4. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
5. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
6. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
[TBL] [Abstract][Full Text] [Related]
7. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
[TBL] [Abstract][Full Text] [Related]
8. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
Ridker PM; MacFadyen JG; Glynn RJ; Chasman DI
Circ Cardiovasc Genet; 2011 Jun; 4(3):312-7. PubMed ID: 21493817
[TBL] [Abstract][Full Text] [Related]
9. Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂.
Rizos CV; Liberopoulos EN; Tellis CC; Florentin M; Elisaf MS; Tselepis AD
Metab Syndr Relat Disord; 2011 Jun; 9(3):217-23. PubMed ID: 21352079
[TBL] [Abstract][Full Text] [Related]
10. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
11. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy.
Eckard AR; Jiang Y; Debanne SM; Funderburg NT; McComsey GA
J Infect Dis; 2014 Apr; 209(8):1156-64. PubMed ID: 24415784
[TBL] [Abstract][Full Text] [Related]
12. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
[TBL] [Abstract][Full Text] [Related]
13. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
O'Keefe JH; Carter MD; Lavie CJ; Bell DS
Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
[TBL] [Abstract][Full Text] [Related]
14. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial.
Novack V; MacFadyen J; Malhotra A; Almog Y; Glynn RJ; Ridker PM
CMAJ; 2012 Apr; 184(7):E367-72. PubMed ID: 22431901
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
Carter NJ
Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
Khera AV; Everett BM; Caulfield MP; Hantash FM; Wohlgemuth J; Ridker PM; Mora S
Circulation; 2014 Feb; 129(6):635-42. PubMed ID: 24243886
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention.
López A; Wright JM
Int J Occup Environ Health; 2012; 18(1):70-8. PubMed ID: 22550699
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.
Glynn RJ; Koenig W; Nordestgaard BG; Shepherd J; Ridker PM
Ann Intern Med; 2010 Apr; 152(8):488-96, W174. PubMed ID: 20404379
[TBL] [Abstract][Full Text] [Related]
19. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
[TBL] [Abstract][Full Text] [Related]
20. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial.
Peña JM; Aspberg S; MacFadyen J; Glynn RJ; Solomon DH; Ridker PM
JAMA Intern Med; 2015 Feb; 175(2):171-7. PubMed ID: 25437881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
